Eli Lilly and Company’s Q1 2026 results showcased a 56% revenue surge to $19.8 billion, driven by unparalleled demand for its incretin portfolio and breakthrough oncology treatments.
Biogen reported a solid start to the year with its Q1 2026 results, featuring 12% growth in new products and a major move to acquire Apellis Pharmaceuticals to bolster its rare disease and nephrology portfolios.
AbbVie announced its first-quarter 2026 financial results, surpassing expectations with $15 billion in revenue and raising its full-year EPS guidance as next-generation immunology assets continue to offset Humira’s erosion.
AstraZeneca reports a robust start to 2026 with $15.3 billion in total revenue, driven by its powerhouse oncology and rare disease portfolios, alongside key clinical successes in COPD and hypophosphatasia.
Novartis reports a resilient Q1 2026 with major gains in oncology and immunology, despite expected generic competition in the US market.
Samsung Biologics reports a stellar start to 2026, recording KRW 1,257 billion in revenue and KRW 581 billion in operating profit, fueled by its new U.S. manufacturing presence and Plant 4 utilization.
Abbott (NYSE: ABT) has released its first-quarter 2026 financial results, showcasing strong organic growth and the strategic integration of Exact Sciences into its world-leading diagnostics portfolio.
Johnson & Johnson delivers a robust start to the year with the Johnson & Johnson Q1 2026 Results, reporting $24.1 billion in revenue and increasing its full-year earnings guidance amid major clinical approvals.
